Objective To investigate the effect and mechanism of the antihyperglycemic agent metformin on the expression of phosphoenolpyruvate carboxykinase (PEPCK) gene in hepatocytes and to determine whether the effects of me...Objective To investigate the effect and mechanism of the antihyperglycemic agent metformin on the expression of phosphoenolpyruvate carboxykinase (PEPCK) gene in hepatocytes and to determine whether the effects of metformin in hepatocytes are transmitted throughout the known insulin signaling pathways Methods Confluent H4IIE rat heptoma cells were cultured for 16 h with 0 1 mmol/L metformin either in absence or presence of 0 1 nmol/L insulin, and then stimulated with various agents The expression of PEPCK gene was examined by Northern blot analysis Results Therapeutic concentrations of metformin significantly inhibited basal PEPCK mRNA expression and also decreased cAMP and dexamethasone induced PEPCK gene expression through interaction with insulin In the presence of insulin signaling pathway inhibitors wortmannin and UO126, metformin reduced PEPCK mRNA levels, but wortmannin blocked inhibitory regulation of insulin on PEPCK gene expression Conclusion Metformin inhibits PEPCK gene expression via either an insulin independent or an interacting with insulin manner The results suggest that a possible mechanism by which metformin reduces gluconeogenesis could be associated with the inhibition of PEPCK gene expression展开更多
Background NF-KB p65 was shown to inhibit transcription of phosphoenolpyruvate carboxykinase （PEPCK）, a rate-limiting enzyme in gluconeogenesis in the liver. To understand the mechanism of action of NF-KB p65, we in...Background NF-KB p65 was shown to inhibit transcription of phosphoenolpyruvate carboxykinase （PEPCK）, a rate-limiting enzyme in gluconeogenesis in the liver. To understand the mechanism of action of NF-KB p65, we investigated the nuclear receptor corepressor in the regulation of PEPCK transcription. Methods Rat H411E cells, human hepatoma HepG2 cells and human embryo kidney （HEK） 293 cells were used in this study. The transcriptional activity of a rat PEPCK gene promoter （-490/＋100） was analyzed in HepG2 cells, a HepG2 super suppressor IkBa （sslkBa） stable cell line, and HEK 293 cells. The effects of p65 and sslkBa on a rat PEPCK gene promoter were observed using the PEPCK luciferase reporter system. The interaction of the cAMP-response- element-binding （CREB） protein, histone deacetylase 3 （HDAC3） and silencing mediator for retinoic and thyroid hormone receptors （SMRT） with the PEPCK gene promoter were investigated using the chromatin immunoprecipitation （CHIP） assay, p65 cotransfection and RNAi-mediated gene knockdown were used to determine the corepressor involved in the inhibition of PEPCK by NF-KB p65 and the transcriptional regulation of CREB by NF-KB p65. Results NF-KB p65 inhibited PEPCK expression and the inhibition was blocked by sslkBa. The inhibitory effect of p65 was completely blocked in a HepG2 stable cell line in which sslkBa was expressed. HDAC3 or SMRT knockdown led to a significant up-regulation of PEPCK reporter activity in the presence of p65 cotransfection. In the ChIP assay the interaction of HDAC3 and SMRT with the PEPCK gene promoter was induced by p65 activation, but the CREB signal was reduced. Transcriptional activity of CREB was inhibited by NF-kB p65 cotransfection. The inhibitory effect of NF-kB p65 was blocked by HDAC3 RNAi or SMRT RNAi. Conculsions The study showed that the inhibition of PEPCK by NF-kB p65 was dependent on HDAC3 and SMRT, which form a nuclear corepressor complex for transcriptional inhibition. The transcription factors NF-kB p65 and CREB share the same corepressor HDAC3-SMRT, and the corepressor exchange leads to inhibition of PEPCK gene transcription by NF-kB p65.展开更多
文摘Objective To investigate the effect and mechanism of the antihyperglycemic agent metformin on the expression of phosphoenolpyruvate carboxykinase (PEPCK) gene in hepatocytes and to determine whether the effects of metformin in hepatocytes are transmitted throughout the known insulin signaling pathways Methods Confluent H4IIE rat heptoma cells were cultured for 16 h with 0 1 mmol/L metformin either in absence or presence of 0 1 nmol/L insulin, and then stimulated with various agents The expression of PEPCK gene was examined by Northern blot analysis Results Therapeutic concentrations of metformin significantly inhibited basal PEPCK mRNA expression and also decreased cAMP and dexamethasone induced PEPCK gene expression through interaction with insulin In the presence of insulin signaling pathway inhibitors wortmannin and UO126, metformin reduced PEPCK mRNA levels, but wortmannin blocked inhibitory regulation of insulin on PEPCK gene expression Conclusion Metformin inhibits PEPCK gene expression via either an insulin independent or an interacting with insulin manner The results suggest that a possible mechanism by which metformin reduces gluconeogenesis could be associated with the inhibition of PEPCK gene expression
基金This study was supported by grants from the National Natural Science Foundation of China （No. 30570885）, 973 Program of China （No. 2006CB503902） （to WENG Jian-ping）, the National Institutes of Health Grant （No. DK068036） and American Diabetes Association Research Award （No. 7-04-RA-139） （to YE ,lian-ping）Acknowledgements： We would like to be grateful to Ms. Wei Tseng, Dr. HE Qin and Dr. YIN Jun for their excellent technical assistance.
文摘Background NF-KB p65 was shown to inhibit transcription of phosphoenolpyruvate carboxykinase （PEPCK）, a rate-limiting enzyme in gluconeogenesis in the liver. To understand the mechanism of action of NF-KB p65, we investigated the nuclear receptor corepressor in the regulation of PEPCK transcription. Methods Rat H411E cells, human hepatoma HepG2 cells and human embryo kidney （HEK） 293 cells were used in this study. The transcriptional activity of a rat PEPCK gene promoter （-490/＋100） was analyzed in HepG2 cells, a HepG2 super suppressor IkBa （sslkBa） stable cell line, and HEK 293 cells. The effects of p65 and sslkBa on a rat PEPCK gene promoter were observed using the PEPCK luciferase reporter system. The interaction of the cAMP-response- element-binding （CREB） protein, histone deacetylase 3 （HDAC3） and silencing mediator for retinoic and thyroid hormone receptors （SMRT） with the PEPCK gene promoter were investigated using the chromatin immunoprecipitation （CHIP） assay, p65 cotransfection and RNAi-mediated gene knockdown were used to determine the corepressor involved in the inhibition of PEPCK by NF-KB p65 and the transcriptional regulation of CREB by NF-KB p65. Results NF-KB p65 inhibited PEPCK expression and the inhibition was blocked by sslkBa. The inhibitory effect of p65 was completely blocked in a HepG2 stable cell line in which sslkBa was expressed. HDAC3 or SMRT knockdown led to a significant up-regulation of PEPCK reporter activity in the presence of p65 cotransfection. In the ChIP assay the interaction of HDAC3 and SMRT with the PEPCK gene promoter was induced by p65 activation, but the CREB signal was reduced. Transcriptional activity of CREB was inhibited by NF-kB p65 cotransfection. The inhibitory effect of NF-kB p65 was blocked by HDAC3 RNAi or SMRT RNAi. Conculsions The study showed that the inhibition of PEPCK by NF-kB p65 was dependent on HDAC3 and SMRT, which form a nuclear corepressor complex for transcriptional inhibition. The transcription factors NF-kB p65 and CREB share the same corepressor HDAC3-SMRT, and the corepressor exchange leads to inhibition of PEPCK gene transcription by NF-kB p65.
